Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Biosimilar Drugs for RA Studied in Multiple Trials

  |  Issue: August 2015  |  

Meta-analyses have not shown an increased risk of other pulmonary events or death due to MTX. MTX rhinitis may develop in treated patients and may progress to respiratory failure. MTX should be stopped, and patients appropriately managed.

Other News

In other news, 35 mg delayed-release risedronate sodium tablets (Atelvia) are now available to treat post-menopausal osteoporosis.6 Tablets for weekly administration are available in a package of four. the rheumatologist

ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Genetics and Biosimilars Initiative (GaBI). Clinical trials for etanercept biosimilars. 22 May 2015.
  2. Regeneron Pharmaceuticals Inc. News Release: Regeneron and Sanofi announce positive topline results from Phase 3 studies with sarilumab in patients with rheumatoid arthritis. 21 May 2015.
  3. Camus P, Faucher P. Pneumotox online: Drug-induced pulmonary disease database, v. 2. 2012.
  4. Highland K. Session IV, Presentation No. #3. Presented at American College of Rheumatology State-of-the-Art Clinical Symposium. May 2–3, 2015. Chicago.
  5. Pulawski S. Certain therapies linked to pulmonary toxicity among patients with rheumatic diseases. Healio. 20 May 2015.
  6. Han DH. Teva launches generic Atelvia. MPR. 19 May 2015.

Related Articles

    Rheumatology Drug Updates: Biosimilars Seek Regulatory Approval in the U.S., Europe; Methotrexate Underused

    Biosimilars Receive Positive News On Nov. 19, 2015, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for SB4, an etanercept biosimilar product that will be called Benepali.1 If approved, Benepali can be used to treat rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis and plaque psoriasis….

    Case Report: RA Patient Suffers Methotrexate-Induced Cutaneous Lesions

    Methotrexate (MTX) remains the predominant medication used by rheumatologists to treat rheumatoid arthritis (RA). Doses of 7.5–25 mg per week with daily folic acid are generally prescribed. Despite its common use, MTX must be prescribed cautiously given the potential adverse effects when taken incorrectly or without folic acid supplementation. Cases of MTX-induced cutaneous ulceration have…